Daré Bioscience, Inc. (NASDAQ:DARE) Q1 2024 Earnings Call Transcript May 14, 2024 4:30 PM ET

Company Participants

Sabrina Martucci Johnson - President and CEO
MarDee Haring-Layton - Chief Accounting Officer

Conference Call Participants

Douglas Tsao - H.C. Wainright
Kemp Dolliver - Brookline Capital Markets
Catherine Novack - Jones Research

Operator

Welcome to the conference call hosted by Daré Bioscience to review the company's First Quarter Financial Results and to provide the General Business Update. This call is being recorded. My name is Alex and I will be your operator for today.

With us today from Daré are Sabrina Martucci Johnson, President and Chief Executive Officer; and MarDee Haring-Layton, Chief Accounting Officer. Ms. Johnson, please proceed.

Sabrina Martucci Johnson

Thank you. Good afternoon and welcome to the Daré Bioscience Financial Results and Business Update Call for the quarter ended March 31, 2024. Today, we'll review our first quarter results and discuss developments and expectations from our pipeline and portfolio.

I would like to remind you that today's discussion will include forward-looking statements within the meaning of the Federal Securities Laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements made during this call that are not statements of historical fact should be considered forward-looking statements. Actual results or events could differ materially from those anticipated or implied by these statements due to known and unknown risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements are qualified in their entirety by the cautionary statements in the company's SEC filings, including our Form 10-Q for the quarter-end of March 31, 2024, which was filed today.

I would also like to point out that the content of this call includes time-sensitive information that is current only as of today, May 14, 2024. Daré undertakes no obligation to update any fully-booking statements to reflect new information or developments after this call, except as required by law.

Before we begin today's update, I'd like to take a minute to remind those of you who may be newer to the Daré story of our purpose and mission. We believe Daré is the only publicly traded company focused solely on women's health, pharmaceutical product development broadly, and we remain dedicated to advancing disruptive products for the health and well-being of women through clinical development, regulatory review, and ultimately to market.

Our commitment and focus is to improve health outcomes and the lives of women by leveraging the basic science and pharmacology that is understood about certain active pharmaceutical ingredients and marketed products to accelerate innovative treatments that women want and need by boldly addressing existing therapeutic gaps. We seek to optimize these treatments for our target indications to enhance outcomes, convenience, and side effect profile, or to address a novel indication where the pharmacology is well suited, but has not been previously applied to the indication in question for women.